Business Wire

Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced three abstracts to be presented at the 36 th EORTC-NCI-AACR (ENA) Symposium 2024 from October 23-25, in Barcelona, Spain ...
Morningstar

ChemDiv's Discovery Platform Enables Differentiated, Reversible Pan‑EGFR Kinase Inhibitors for GFR‑Mutant Lung Cancer

SAN DIEGO, Oct. 30, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced kinase inhibitor design enhancements to its discovery platform. The new ...
KTLA

Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica ...

BRUIN CLL-314 is the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve patients INDIANAPOLIS, July 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: ...
News Medical

Scientists discover irreversible peptide inhibitors for undruggable cancer target

For the first time scientists have identified promising drug candidates that bind irreversibly with a notoriously "undruggable" cancer protein target, permanently blocking it. Transcription factors ...
Yahoo Finance

U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory ...

Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with a covalent BTK inhibitor This expanded ...
Seeking Alpha

Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica ...

Pirtobrutinib met the primary endpoint of response rate non-inferiority, favoring pirtobrutinib with a nominal P-value for superiority < 0.05 Progression-free survival data was immature, but trending ...